for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Medigus Ltd.

MDGS.OQ

Latest Trade

1.79USD

Change

0.03(+1.70%)

Volume

360

Today's Range

1.73

 - 

1.79

52 Week Range

1.62

 - 

3.82

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.76
Open
1.73
Volume
360
3M AVG Volume
7.63
Today's High
1.79
Today's Low
1.73
52 Week High
3.82
52 Week Low
1.62
Shares Out (MIL)
75.93
Market Cap (MIL)
24.57
Forward P/E
--
Dividend (Yield %)
--

Next Event

Medigus Ltd Annual Shareholders Meeting

Latest Developments

More

Medigus Sold Micro Cameras To Two Defense Organizations

Medigus Says Co Completed Additional Milestone In Agreement With A.M. Surgical

Medigus To Invest $5 Million In Algomizer Group

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Medigus Ltd.

Medigus Ltd is an Israel-based company active in the medical sector. It specializes in developing endoscopic procedures and devices. Its product line includes SRS endoscopy systems for the treatment of gastroesophageal reflux disease (GERD). Medigus' SRS endoscopy system for the treatment of GERD performs an anterior fundoplication in lieu of the current surgical procedure, but without opening the abdominal cavity. The SRS endoscope combines a surgical stapler, ultrasonic sights for accurate positioning and a miniaturized video camera in a single instrument. The company also offers micro cameras for medical endoscopy, industrial endoscopy, remote visual inspection, non-destructive testing, and machine vision applications. The company provides its micro cameras to the medical device industry, as well as to industrial companies, universities, and research institutes.

Industry

Medical Equipment & Supplies

Contact Info

Building 7A

Omer Industrial Park, Pob 3030

+972.8.6466880

http://www.medigus.com

Executive Leadership

Liron Carmel

Chief Executive Officer

Oded Yatzkan

Chief Financial Officer, Director

Minelu Menashe Sonnenschein

Vice President - Operations

Yaron Zilberman

Vice President - Sales and Marketing

Tatyana Yossef

Controller

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
16.01
Price To Book (MRQ)
0.86
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-81.81
Return on Equity (TTM)
-71.53

Latest News

BRIEF-Medigus Q3 revenue falls 14 percent to $117,000

* Q3 revenue fell 14 percent to $117,000 Source text for Eikon: Further company coverage:

BRIEF-Medigus announces pricing of $1.6 mln registered direct offering

* Medigus announces pricing of $1.6 million registered direct

BRIEF-Medigus announces second quarter 2017 financial results

* Medigus Ltd - operating loss for three months ended June 30, 2017, was $1.3 million, compared to $2.7 million in three months ended June 30, 2016

BRIEF-Medigus broadens availability of MUSE device via deal

* Medigus broadens availability of muse(tm) through distribution agreement with admedics ag in switzerland and liechtenstein

BRIEF-Medigus signs distribution agreement with Izasa Hospital in Spain

* Medigus expands global commercial availability of Muse through distribution agreement with Izasa Hospital, S.L.U. in Spain

BRIEF-Empery Asset Management reports 9.99 percent passive stake in Medigus Ltd as of March 24

* Empery Asset Management LP reports a 9.99 percent passive stake in Medigus Ltd as of March 24, 2017 - sec filing Source text : [http://bit.ly/2nZ3pTR] Further company coverage:

BRIEF-Medigus announces $7.5 million public offering

* Medigus Ltd - announced pricing of a best efforts public offering of 979,714 class a units at a purchase price per unit of $3.50

BRIEF-Medigus receives approval to conduct multi-center muse clinical study in China

* Medigus receives approval for commencement of the first multi-center muse clinical study from cfda in China

BRIEF-Medigus Q3 revenue fell 43 percent to $136,000

* Q3 revenue fell 43 percent to $136,000 Source text for Eikon: Further company coverage:

BRIEF-Medigus expands commercial availability of MUSE through distribution agreement with Innovamedica S.P.A. in Italy

* Medigus expands global commercial availability of MUSE through distribution agreement with Innovamedica S.P.A. in Italy; new agreement broadens medigus' accessibility in key markets around the world

BRIEF-Medigus CFO Gilad Mamlok to leave the company

* Gilad Mamlok, the chief financial officer of the company, will leave the company at the end of January 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up